INTRODUCTION

Coronary artery disease (CAD) still represents the leading cause of mortality worldwide. Chronic kidney disease (CKD) represents a condition with a very high cardiovascular risk, both mediated by the association with main established risk factors, such as diabetes, hypertension, dyslipidaemia and by an increase in pro-oxidant and pro-inflammatory mediators in the bloodstream, progressively enhancing the athero-thrombotic processes as the renal function decreases. The platelet parameters are studied in patients with cardiovascular disease, contrasting results have been reported so far on the effects of renal function on platelet volume. The aim of our study is to investigate the relationship between Platelet parameters and glomerular filtration rate (GFR) in patients with non-diabetic CKD and whether an altered Platelet parameters were correlated with worsening of renal function.

Material and methods: This study was performed on 101 subjects into three groups. Control group (Group 1) n=25, CKD stage 3 and 4 (Group 2) n=46, CKD stage 5 (Group 3) n=30 on maintenance Haemodialysis include both the gender in the age group of 18 to 65 years. After the exclusion of diabetes, prior history of CVA, CAD, obesity and smoking, patients were informed about the study pattern, and blood sample were drawn for the measurement of platelet parameters.

Results: The mean MPV of group 2 and group 3 patients were 10.62±1.76 and 10.06±2.08 respectively (P <0.001). Similarly PDW and P-LCR of group 2, 3 patients were 14.67±1.89, 14.56±1.80 (P<0.001) and 31.35±7.16, 24.14±5.44 (P<0.001) respectively. The mean Platelet count of group 2 and 3 patients were 2.44±0.84 and 1.93±0.78 (P >0.001) respectively.

Conclusion: In our study the MPV as an indicator of increased platelet activity was significantly increased in CKD stage 3, 4 and 5, when compared to general population, but at the same time it was not significantly altered by Haemodialysis.

Keywords: Chronic Kidney Disease, Platelet parameters, MPV.
**MATERIAL AND METHODS**

This study was performed on 101 subjects into three groups. Control group (Group 1), CKD stage 3 and 4 (Group 2), CKD stage 5 (group 3), include both the gender, in the age group of 18 to 65 years during the period of February 2018 to October 2018. Case group included 76 patients with CKD stage 3 to 5 undergoing medical management and maintenance haemodialysis for more than 6 months at Meenakshi Medical College Hospital and Research Institute. Every patient was informed about the study pattern and the volunteers given consent for participation in this study was included. During the study period no drug was additionally given or not modified.

All the patients of stage 5 CKD (ESRD) are undergoing regular haemodialysis for 3 times a week lasting for 4 hours, using bicarbonate buffer with blood flow of 250 ml per/min and dialysate flow of 500 ml/min with 1.6 square metre surface area hollow fibre polysulphone membrane dialyser. Control group included 25 subjects of healthy adults including male and female volunteers not having any kidney damage.

**Exclusion criteria**

Patient’s blood sugar values are evaluated according to ADA diagnostic criteria to exclude the diagnosis of diabetes mellitus. The patient with HaA1c value of >6% FBS of >100% PPBS of >140 were excluded from the study. Patients with prior history of CVA, CAD, obesity, smoking and previous long-term drug intake of NSAIDS, anti-platelets and anti-coagulants, hepatic impairment were excluded from both case group and control group.

During prehaemodialysis period in ESRD patients and in all others participants of this study 5 ml of venous blood sample was withdrawn in their 12 hours fasting state. The blood samples were processed by fully automated bidirectional analyser by the method of flow cytometry and hydrodynamic focussing techniques for the measurement of platelet parameter like PDW, MPV, P-LCR, platelet count. With creatinine, GFR was measured with MDRD formula.

**MDRD Study Equation**

\[
\text{eGFR} = \frac{175 \times \text{age}^{0.203} \times \text{weight}^{0.156} \times \text{cr}^{-0.742}}{[\text{if male}] \times 1.212 \times [\text{if Black}]}
\]

**RESULTS**

Demographic and biochemical data of study group are provided in Table 1. Mean ages of the patients in CKD stage 3 and 4 (Group 2), CKD stage 5 (Group 3) and healthy control (Group 1) groups were 52.67 ± 8.07, 50.43 ± 10.33 and 48.56 ± 11.05 years respectively (P not significant). Percentages of the female subjects in Group 1, Group 2 and Group 3 were 36%, 39% and 37%, respectively (P not significant). In our study showed a statistically significant difference between Group 1, Group 2 and Group 3 in Systolic Blood Pressure, Diastolic Blood Pressure, Urea, Creatinine, Glomerular Filtration Rate (P < 0.01, P < 0.01, P < 0.01, P < 0.01, P < 0.01), respectively. Although the Platelet Count values were lower in CKD group than control group, difference was not statistically significant (P = 0.022).

The paired variables SBP and urea in group 1 shows statistical significance, similarly SBP and creatinine in group 1, SBP and DBP in group 3, DBP and urea in group 3, DBP and platelet count in group 3, platelet count and P-LCR in group 3 shows statistical significance.

<table>
<thead>
<tr>
<th>Parameters</th>
<th>Group 1 (n=25)</th>
<th>Group 2 (n=46)</th>
<th>Group 3 (n=30)</th>
<th>p-value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Gender</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Females [n (%)]</td>
<td>9 (36%)</td>
<td>18 (39%)</td>
<td>11 (37%)</td>
<td>0.013*</td>
</tr>
<tr>
<td>Males [n (%)]</td>
<td>16 (64%)</td>
<td>28 (61%)</td>
<td>19 (63%)</td>
<td></td>
</tr>
<tr>
<td>Age</td>
<td>46.56±11.05</td>
<td>52.67±8.07</td>
<td>50.43±10.33</td>
<td>0.213</td>
</tr>
<tr>
<td>SBP</td>
<td>129.04±12.53</td>
<td>152.00±14.68</td>
<td>147.47±13.94</td>
<td>&lt;0.001**</td>
</tr>
<tr>
<td>DBP</td>
<td>84.08±13.58</td>
<td>97.26±9.73</td>
<td>90.80±8.31</td>
<td>&lt;0.001**</td>
</tr>
<tr>
<td>Urea</td>
<td>28.60±7.90</td>
<td>55.58±19.14</td>
<td>47.87±16.83</td>
<td>&lt;0.001**</td>
</tr>
<tr>
<td>Cr</td>
<td>0.95±0.17</td>
<td>2.39±0.70</td>
<td>5.90±1.22</td>
<td>&lt;0.001**</td>
</tr>
<tr>
<td>GFR</td>
<td>81.16±22.15</td>
<td>28.20±9.24</td>
<td>10.57±2.46</td>
<td>&lt;0.001**</td>
</tr>
<tr>
<td>MPV</td>
<td>8.72±1.86</td>
<td>10.62±1.76</td>
<td>10.06±2.08</td>
<td>&lt;0.001**</td>
</tr>
<tr>
<td>PDW</td>
<td>12.08±1.99</td>
<td>14.67±1.89</td>
<td>14.56±1.80</td>
<td>&lt;0.001**</td>
</tr>
<tr>
<td>PL count</td>
<td>2.45±0.90</td>
<td>2.44±0.84</td>
<td>1.93±0.78</td>
<td>0.022*</td>
</tr>
<tr>
<td>P-LCR</td>
<td>32.74±7.54</td>
<td>31.35±7.16</td>
<td>24.14±5.44</td>
<td>&lt;0.001**</td>
</tr>
</tbody>
</table>

*: There exists statistically significant difference in means of different groups of the variables at 5% level. **: There exists statistically significant difference in means of different groups of the variables at 1% level.

Data were expressed as mean± standard deviation. CKD: Chronic kidney disease, SBP: Systolic Blood Pressure, DBP: Diastolic Blood pressure, Cr: Creatinine, GFR: Glomerular filtration rate.

Table-1: Demographic and Biochemical data of study groups
Pearson’s r | SBP | DBP | urea | Cr | GFR | MPV | PDW | Pl count | P-LCR
--- | --- | --- | --- | --- | --- | --- | --- | --- | ---
SBP | - | 0.116 | -0.050 | -0.086 | 0.062 | 0.151 | -0.185 | -0.013 | -0.057
DBP | 0.116 | - | 0.117 | 0.156 | -0.033 | -0.046 | -0.170 | -0.002 | 0.032
urea | -0.050 | 0.117 | - | 0.218 | -0.143 | 0.045 | -0.134 | 0.096 | -0.059
Cr | -0.086 | 0.156 | 0.218 | - | -0.834 | -0.001 | 0.055 | -0.182 | 0.034
GFR | 0.062 | -0.033 | -0.143 | -0.834 | - | -0.089 | -0.032 | 0.167 | -0.033
MPV | 0.151 | -0.046 | 0.045 | -0.001 | -0.089 | - | -0.191 | 0.146 | 0.245
PDW | -0.185 | -0.170 | -0.134 | 0.055 | -0.032 | -0.191 | - | 0.101 | 0.078
Pl count | -0.013 | -0.002 | 0.096 | -0.182 | 0.167 | 0.146 | 0.101 | - | 0.102
P-LCR | -0.057 | 0.032 | -0.059 | 0.034 | -0.033 | 0.245 | 0.078 | 0.102 | -

Note: Blue colour indicates positive correlation and red colour indicates negative correlation. The darkness of the shade represents the strength of correlation. In Group 2 the above table shows Positive Correlation between 1. P-LCR and MPV 2. SBP and MPV and Negative Correlation between 1. PDW and MPV 2. PDW and SBP 3. Platelet Count and Creatinine.

Table-2: Correlation of the variables-Group 2

Pearson’s r | SBP | DBP | urea | Cr | GFR | MPV | PDW | Pl count | P-LCR
--- | --- | --- | --- | --- | --- | --- | --- | --- | ---
SBP | - | 0.374 | 0.334 | 0.135 | -0.081 | 0.336 | -0.122 | -0.045 | 0.327
DBP | 0.374 | - | 0.447 | -0.031 | 0.290 | -0.299 | 0.081 | 0.020 | -0.099
urea | 0.334 | 0.447 | - | 0.290 | -0.299 | 0.081 | 0.020 | 0.069 | 0.082
Cr | 0.135 | -0.031 | 0.290 | - | -0.946 | -0.066 | -0.012 | 0.069 | -0.095
GFR | -0.081 | 0.011 | -0.299 | -0.946 | - | 0.057 | 0.003 | -0.052 | -0.189
MPV | 0.336 | 0.269 | 0.081 | -0.066 | 0.057 | - | -0.181 | -0.071 | -0.189
PDW | -0.122 | -0.339 | 0.020 | -0.012 | 0.033 | -0.181 | - | 0.171 | 0.061
Pl count | -0.045 | -0.473 | -0.006 | 0.069 | -0.052 | -0.071 | 0.171 | - | 0.374
P-LCR | 0.327 | -0.071 | -0.099 | 0.082 | -0.095 | -0.189 | 0.061 | 0.374 | -

Note: Blue color indicates positive correlation and red color indicates negative correlation. The darkness of the shade represents the strength of correlation. In Group 1 the above table shows Positive Correlation between 1. Urea and DBP 2. SBP and MPV 3. Urea and SBP 4. P-LCR and SBP 5. Platelet count and P-LCR 6. MPV and DBP and Negative Correlation between 1. Platelet Count and DBP 2. PDW and DBP.

Table-3: Correlation of the variables-Group 3

<table>
<thead>
<tr>
<th>Group</th>
<th>Pair</th>
<th>N</th>
<th>Pearson’s r</th>
<th>95% CI</th>
<th>0</th>
<th>p-value</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>SBP, urea</td>
<td>25</td>
<td>-0.459</td>
<td>-0.723 to -0.077</td>
<td></td>
<td>0.021</td>
</tr>
<tr>
<td>1</td>
<td>SBP, Cr</td>
<td>25</td>
<td>-0.500</td>
<td>-0.747 to -0.131</td>
<td></td>
<td>0.0109</td>
</tr>
<tr>
<td>3</td>
<td>SBP, DBP</td>
<td>30</td>
<td>0.374</td>
<td>0.016 to 0.647</td>
<td></td>
<td>0.0419</td>
</tr>
<tr>
<td>3</td>
<td>DBP, urea</td>
<td>30</td>
<td>0.447</td>
<td>0.103 to 0.695</td>
<td></td>
<td>0.0133</td>
</tr>
<tr>
<td>3</td>
<td>DBP, Pl count</td>
<td>30</td>
<td>-0.473</td>
<td>-0.712 to -0.135</td>
<td></td>
<td>0.0084</td>
</tr>
<tr>
<td>3</td>
<td>Pl count, P-LCR</td>
<td>30</td>
<td>0.374</td>
<td>0.016 to 0.647</td>
<td></td>
<td>0.0419</td>
</tr>
</tbody>
</table>

1 Reject the null hypothesis in favour of the alternative hypothesis at the 5% significance level, i.e. the two variables are correlated 5% level of significance.

Table 4: Significance of correlation of paired variables

**DISCUSSION**

Platelet parameters were found to be significantly altered in chronic inflammatory conditions like chronic kidney disease and hence more pronounced in the state of haemodialysis. Because platelets have been identified as integrators of inflammatory mediators and endothelial cells. In this study, the platelet count was not showing any difference in group 1 in comparison to group 2. It was lower in group 3 than other two groups but which was not statistically significant even though increased platelet e-granulation during haemodialysis. This was in discordance with Schoorl et al. who observed that CKD patients of stage 5 on maintenance...
HD had lower range of platelet count. Similarly, in study by Lokesh S et al\textsuperscript{2} the average platelet count was found to be decreased among patients on haemodialysis as compared to controls which was found to be statistically significant. MPV reflects the average platelet size, most extensively studied platelet parameter as a pro-thrombotic in chronic inflammatory conditions also an indicator of platelet activation and function, which can be useful to assess the prognosis of cardiovascular and cerebrovascular disease in CKD. Larger platelets are highly active and release more chemical mediators that are thrombotic factors.\textsuperscript{13} Increased MPV is an independent risk factor for cardiovascular disease in CKD.\textsuperscript{14,15} In this study, there was significant difference in MPV between the groups. When compared with control group with other two groups there was a statistically highly significant increase in MPV were noted. Koroglu et al. observed similarly a high MPV in CKD stage 3 to 5 patients and inferred that MPV can be used as a biomarker to estimate cardiovascular risk in patients on haemodialysis. But at the same time MPV is minimally decreased in stage 5 kidney disease when compare to stages 3 and 4, may be due to the clearance of uremia better in case of haemodialysis and that difference is not statistically significant. Ju et al reported that there is a negative linear correlation between stages of CKD and MPV.\textsuperscript{16} Bilen et al, in their study, conducted with 50 patients with CKD stage 5 and 50 patients of Stage 3–4 CKD, reported that there are no differences between the groups for MPV.\textsuperscript{16} The PDW is calculated mathematically from the platelet frequency distribution and is a measure of the variability of platelet sizes. As a result, when there is a variation in size from small to large, that will influence the PDW. Combined with the MPV, it can point out the possibility of enlarged platelets or even fragments of megakaryocyte, which are conditions with clinical significance in the risk of cardiovascular disease. PDW was significantly higher in group 2 and group 3 than with group 1 in our study. In addition, the difference between group 2 and 3 was not significant. Under healthy conditions, there is a direct relationship between MPV and PDW; both usually change in the same direction.\textsuperscript{17} These results are in match with MVP, having the common denominator of platelet activation could explain the same direction of change in our study.

L-PCR, Indicator of larger (> 12 fL) circulating platelets, was significantly lower in group 3 in comparison with group 1 and group 2, but in comparison to group 1 and group 2 the difference was not significant. Koroglu et al observed that P-LCR falls significantly in thrombocytosis but in our study, these happens in the setting of no significant change in platelet count. School M et al, in his study observed a similar decreased mean L-PCR in patient group of haemodialysis.\textsuperscript{18}

**CONCLUSION**

In our study the MPV as an indicator of increased platelet activity was significantly increased in CKD stage 3, 4 and 5, when compared to general population, but at the same time it was NOT significantly altered by Haemodialysis. Similarly, PDW also significantly increased in CKD stage 3, 4 and 5. P-LCR was significantly lower in CKD stage 5, when compared to general population, but at the same time it was NOT significantly altered by Haemodialysis. Similarly, PDW also significantly increased in CKD stage 5, when compared to general population, but at the same time it was NOT significantly altered by Haemodialysis.

REFERENCES


Source of Support: Nil; Conflict of Interest: None
Submitted: 16-05-2019; Accepted: 12-06-2019; Published online: 15-07-2019